VCYT: Veracyte, Inc.
About
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Current Value
$43.131 Year Return
Current Value
$43.131 Year Return
Key Details
Market Cap
$3.33B
P/E Ratio
-297.44
1Y Stock Return
68.15%
1Y Revenue Growth
23.95%
Dividend Yield
0.00%
Price to Book
2.8
Strategies that include VCYT
Stock's related to VCYT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CEVA | 55.04% | $738.10M | +40.97% | 0.00% |
| SKY | 54.96% | $6.16B | +63.32% | 0.00% |
| RVLV | 54.10% | $2.52B | +121.42% | 0.00% |
| HHH | 53.96% | $4.21B | +13.39% | 0.00% |
| ANGI | 53.89% | $939.84M | -20.59% | 0.00% |
| SWI | 52.08% | $2.46B | +35.42% | 0.00% |
| KRNT | 50.01% | $1.51B | +68.57% | 0.00% |
| IAC | 49.90% | $4.04B | -4.02% | 0.00% |
| BL | 49.53% | $3.96B | +5.23% | 0.00% |
| GH | 49.21% | $4.39B | +32.62% | 0.00% |
| EEFT | 49.16% | $4.58B | +13.66% | 0.00% |
| NTLA | 49.10% | $1.50B | -47.71% | 0.00% |
| PLUS | 48.76% | $2.12B | +10.00% | 0.00% |
| CRSP | 48.35% | $4.16B | -16.24% | 0.00% |
| FARO | 48.24% | $514.55M | +47.35% | 0.00% |
| ILMN | 48.22% | $23.56B | +29.59% | 0.00% |
| SHOP | 47.69% | $146.59B | +56.48% | 0.00% |
| BLFS | 47.51% | $1.22B | +106.30% | 0.00% |
| ACCO | 47.43% | $574.93M | +15.06% | 4.83% |
| NGVT | 47.35% | $1.68B | +14.76% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OCX | -0.17% | $42.09M | -4.58% | 0.00% |
| KSPI | -0.24% | $20.69B | +15.86% | 3.37% |
| EDU | 0.34% | $10.31B | -23.09% | 0.00% |
| RLMD | 0.36% | $14.18M | -80.82% | 0.00% |
| PRPH | 0.39% | $16.11M | -85.86% | 0.00% |
| PSQH | 0.40% | $179.82M | -14.26% | 0.00% |
| NEXA | -0.43% | $1.06B | +39.20% | 0.00% |
| TCPC | 0.50% | - | - | 14.35% |
| TRIP | -0.50% | $1.95B | -22.89% | 0.00% |
| BNED | -0.51% | $326.07M | -90.74% | 0.00% |
| PSEC | -0.61% | - | - | 15.97% |
| ROOT | -0.75% | $1.25B | +739.23% | 0.00% |
| BACK | 0.87% | $2.07M | -23.57% | 0.00% |
| CL | -0.92% | $76.71B | +19.47% | 2.10% |
| WM | 0.97% | $86.73B | +22.36% | 1.39% |
| BTCT | -0.98% | $39.13M | +169.13% | 0.00% |
| CBOE | 1.01% | $21.25B | +13.78% | 1.16% |
| CYCN | 1.07% | $11.30M | +58.56% | 0.00% |
| GLP | 1.07% | $1.83B | +42.19% | 5.30% |
| GIS | 1.18% | $36.72B | -0.90% | 3.60% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -19.21% | $74.13B | +26.36% | 0.46% |
| SGC | -15.05% | $272.57M | +25.89% | 3.36% |
| NEUE | -11.53% | $43.41M | -19.51% | 0.00% |
| CCEC | -11.35% | $1.01B | +39.16% | 3.28% |
| TCTM | -10.83% | $8.31M | -6.96% | 0.00% |
| ODP | -10.62% | $854.45M | -40.49% | 0.00% |
| PGR | -10.33% | $144.85B | +49.74% | 0.46% |
| MNR | -8.52% | $1.52B | -11.84% | 21.63% |
| CYD | -8.49% | $370.18M | +10.76% | 4.19% |
| CLW | -8.16% | $449.48M | -22.62% | 0.00% |
| IMXI | -7.83% | $666.13M | +3.08% | 0.00% |
| OXBR | -7.74% | $22.54M | +251.46% | 0.00% |
| COR | -7.30% | $45.81B | +16.21% | 0.89% |
| ACGL | -6.73% | $35.12B | +22.28% | 0.00% |
| CHD | -5.79% | $26.23B | +13.34% | 1.05% |
| NHTC | -5.36% | $54.23M | -15.29% | 17.09% |
| HUSA | -5.33% | $16.88M | -24.12% | 0.00% |
| PULM | -5.02% | $21.77M | +223.91% | 0.00% |
| LITB | -4.47% | $33.93M | -72.29% | 0.00% |
| GAN | -4.43% | $84.30M | +14.20% | 0.00% |
ETF's related to VCYT
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -30.44% | $195.31M | 0.85% |
| USDU | -24.47% | $211.42M | 0.5% |
| UUP | -20.74% | $386.70M | 0.77% |
| TAIL | -15.45% | $68.43M | 0.59% |
| CTA | -12.83% | $380.14M | 0.76% |
| KMLM | -10.06% | $332.27M | 0.9% |
| XBIL | -8.96% | $632.22M | 0.15% |
| SGOV | -8.90% | $28.68B | 0.09% |
| EQLS | -8.66% | $8.94M | 1% |
| CLOI | -8.35% | $773.20M | 0.4% |
| AGZD | -8.34% | $132.89M | 0.23% |
| BIL | -8.16% | $34.60B | 0.1356% |
| WEAT | -7.18% | $122.96M | 0.28% |
| JBBB | -6.22% | $1.36B | 0.49% |
| MINT | -5.03% | $11.81B | 0.35% |
| BILZ | -3.92% | $558.25M | 0.14% |
| BOXX | -3.69% | $4.47B | 0.1949% |
| HIGH | -3.22% | $298.33M | 0.52% |
| TBIL | -2.87% | $4.51B | 0.15% |
| CORN | -2.28% | $61.14M | 0.2% |
News
SeekingAlpha
Veracyte has seen its stock more than double since early August. Read more to see a full investment analysis for VCYT stock.
Yahoo
SOUTH SAN FRANCISCO, Calif., December 05, 2024--Veracyte’s Decipher Prostate Test is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
Yahoo
Cancer diagnostics firm Veracyte has just sparked a breakout. That's just one reason to watch this AI-fueled growth stock.
Yahoo
In the last week, the United States market has stayed flat; however, it is up 33% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that can capitalize on strong earnings potential and sustain momentum in a rapidly evolving sector.
Yahoo
As the U.S. stock market experiences a cautious uptick with futures slightly higher, investors are closely watching economic data and Federal Reserve commentary for signs of stability following recent fluctuations. In this environment, identifying stocks that may be trading below their fair value can provide opportunities for investors seeking to capitalize on potential market inefficiencies.
Yahoo
As you might know, Veracyte, Inc. ( NASDAQ:VCYT ) just kicked off its latest quarterly results with some very strong...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.